Oxford makes European life sciences debut

Oxford Properties Group has extended its global life sciences platform with the acquisition of 310 Cambridge Science Park for £45m in an off-market deal. The 59,000 sq ft facility, which is let to AstraZeneca until November 2023, has been bought